Targeted drugs for lung cancer, mostly NSCLC, mainly include EGFR-tyrosine kinase inhibitors (EGFR-TKIs) and ALK-tyrosine kinase inhibitors (ALK-TKIs). This evidence concerns the gene ALK and non-small cell lung carcinoma.